Denmark’s medicines regulator has unveiled updated guidance on digital and decentralised clinical trials, marking a watershed moment for multinational research collaboration across Europe. The revised framework aligns Danish standards with EU common guidance while introducing groundbreaking provisions for cross-border patient participation.
Under the new framework, patients in one EU member state can now enrol in trials sponsored by organisations in another country, significantly expanding recruitment opportunities—particularly for rare disease research. This harmonisation reflects the continent’s growing reliance on digital technologies in clinical research, a trend accelerated by the COVID-19 pandemic’s normalisation of remote patient monitoring and virtual consultations.
The update positions Denmark as a leader in regulatory modernisation, supporting the European Medicines Agency’s broader initiative to facilitate seamless multinational research across borders. Read the full article on GMJ Newsroom.
Was this article helpful?
